Trials / Recruiting
RecruitingNCT06434792
Study to Evaluate Efficacy and Safety of Bronpass Tab. in Patients With Chronic Obstructive Pulmonary Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Dose-response Phase 2 Clinical Trial to Compare the Efficacy and Safety of Bronpass Tab. Versus Placebo in Patients With Stable COPD
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 96 (estimated)
- Sponsor
- Hanlim Pharm. Co., Ltd. · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group dose-response phase 2 clinical trial study to evaluate the efficacy and safety of Bronpass Tab. in 96 patients with chronic obstructive pulmonary disease.
Detailed description
This study is to prove that Bronpass Tab. is superior in clinical efficacy and safety in improving COPD symptoms compared to placebo for 12 weeks in patients suffering from chronic obstructive pulmonary disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bronpass Tab. | Twice daily for 12 weeks |
| OTHER | Placebo | Twice daily for 12 weeks |
Timeline
- Start date
- 2023-06-01
- Primary completion
- 2024-09-01
- Completion
- 2025-03-01
- First posted
- 2024-05-30
- Last updated
- 2024-05-30
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06434792. Inclusion in this directory is not an endorsement.